Stock Events

Stock Events

BioXcel Therapeutics 

$0.058000
0
-$0.02-22.77% Friday 19:52

Statistics

Day High
0.0679
Day Low
0.0521
52W High
3.12
52W Low
0.019
Volume
62,897
Avg. Volume
6,432,332
Mkt Cap
1.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q2 2026
Next
-1.01
-0.82
-0.63
-0.44
Expected EPS
-1.01
Actual EPS
N/A

Financials

-10,887.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
642,000Revenue
-69.9MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BTAIQ. It's not an investment recommendation.
Apple
19
AAPL
Microsoft
19
MSFT
NVIDIA
18
NVDA
Palantir Technologies
18
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.28B
Alkermes develops therapies for central nervous system (CNS) diseases, including schizophrenia and depression, overlapping with BioXcel's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.7B
ACADIA Pharmaceuticals specializes in CNS disorders, particularly Parkinson’s disease psychosis, competing in the neuropsychiatric space.
Insmed
INSM
Mkt Cap26.21B
Insmed incorporates novel approaches to treat serious and rare diseases, including neurological disorders, potentially competing with BioXcel's innovative approaches.
BridgeBio Pharma
BBIO
Mkt Cap13.02B
BridgeBio Pharma targets genetic diseases and cancers with a precision medicine approach, indirectly competing in the innovation space for treatments.
Protagonist Therapeutics
PTGX
Mkt Cap9.59B
Protagonist Therapeutics is involved in developing peptide-based treatments that could compete with BioXcel's therapies in various indications.
Axsome Therapeutics
AXSM
Mkt Cap10.88B
Axsome Therapeutics focuses on developing treatments for central nervous system disorders, including depression and migraine, competing in BioXcel's market.
Voyager Therapeutics
VYGR
Mkt Cap190.4M
Voyager Therapeutics specializes in severe neurological diseases by developing gene therapies, offering a different approach but competing in the same therapeutic area.

About

BIOXCEL THERAPEUTICS INC
Show more...
CEO
Vimal D. Mehta
Employees
29
Country
United States
ISIN
US09075P2048
WKN
000A40YSR

Listings

MU
DE
BX2.MU
MU
DE
BX20.MU
OTCM
US
BTAI
OTC Link
US
BTAIQ

0 Comments

Share your thoughts

FAQ

What is BioXcel Therapeutics stock price today?▼
The current price of BTAIQ is $0.06 USD — it has decreased by -22.77% in the past 24 hours. Watch BioXcel Therapeutics stock price performance more closely on the chart.
What is BioXcel Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange BioXcel Therapeutics stocks are traded under the ticker BTAIQ.
What is BioXcel Therapeutics market cap?▼
Today BioXcel Therapeutics has the market capitalization of 1.82M
When is the next BioXcel Therapeutics earnings date?▼
BioXcel Therapeutics is going to release the next earnings report on November 18, 2026.
What is BioXcel Therapeutics revenue for the last year?▼
BioXcel Therapeutics revenue for the last year amounts to 642,000 USD.
What is BioXcel Therapeutics net income for the last year?▼
BTAIQ net income for the last year is -69.9M USD.
How many employees does BioXcel Therapeutics have?▼
As of September 21, 2026, the company has 29 employees.
In which sector is BioXcel Therapeutics located?▼
BioXcel Therapeutics operates in the Health & Wellness sector.
When did BioXcel Therapeutics complete a stock split?▼
The last stock split for BioXcel Therapeutics was on February 10, 2025 with a ratio of 1:16.
Where is BioXcel Therapeutics headquartered?▼
BioXcel Therapeutics is headquartered in New Haven, United States.